Top

Published in:

Open Access 01-12-2023 | Bisphosphonate | Consensus Statement

Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society

Authors: Yousef Al-Saleh, Riad Sulimani, Shaun Sabico, Fahad M. Alshahrani, Mona A. Fouda, Mohammed Almohaya, Salwa B. Alaidarous, Hazem M. Alkhawashki, Mohammed Alshaker, Hanan Alrayes, Najla Saleh, Nasser M. Al-Daghri

Published in: Archives of Osteoporosis | Issue 1/2023

Abstract

Summary

The Saudi Osteoporosis Society (SOS) has updated its guidelines for the diagnosis and management of osteoporosis in Saudi Arabia (SA), with emphasis on postmenopausal women. This document is relevant to all healthcare professionals in SA involved in the care of patients with osteoporosis and osteoporosis-related fractures.

Introduction

The SOS launched the first national osteoporosis guidelines in 2015 and spearheaded the Gulf Cooperation Council Countries (GCC) osteoporosis consensus report in 2020 which was under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO). This paper highlights a major update of the guidelines in the SA setting.

Methods

This guideline is an adaptation of the current guidelines derived from ESCEO, the American Association of Clinical Endocrinologists (AACE), and the GCC osteoporosis consensus report and studies on osteoporosis done in SA. Where accessible, the timeliest systematic review, meta-analysis, and randomized controlled trials were used as evidence.

Results

The present update includes new recommendations for the assessment of osteoporosis taking into consideration the Saudi model of FRAX for fracture probabilities, appropriate doses for the maintenance of vitamin D status and calcium, the use of representative blood analytes for therapy monitoring, the use of romosozumab and sequential therapy in the pharmacological management strategies, and the establishment of fracture liaison services to prevent secondary fractures.

Conclusion

This updated guideline is for all healthcare professionals involved in osteoporosis and post-fracture care and management in SA and harmonized the most up-to-date changes in the field based on evidence-based medicine for use in the local setting.

Available only for authorised users

Raef H, Frayha HH, El-Shaker M, Al-Humaidan A, Conca W, Sieck U, Okane J, Osteoporosis Working Group (2004) Recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med 24(4):242–52. https://doi.org/10.5144/0256-4947.2004.242CrossRefPubMedPubMedCentral

Raef H, Al-Bugami M, Balharith S, Moawad M, El-Shaker M, Hassan A, Al-Shaikh A et al (2011) Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med 31(2):111–28. https://doi.org/10.4103/0256-4947.77502CrossRefPubMedPubMedCentral

Al-Saleh Y, Sulimani R, Sabico S, Raef H, Fouda M, Alshahrani F, Al Shaker M, Al Wahabi B et al (2015) 2015 Guidelines for Osteoporosis in Saudi Arabia: recommendations from the Saudi Osteoporosis Society. Ann Saudi Med 35(1):1–12. https://doi.org/10.5144/0256-4947.2015.1CrossRefPubMedPubMedCentral

Jassim NA, Adib G, Abdul Rahman YA, Gorial FI, Maghraoui A, Al Suhaili AR, Murtaji A et al (2017) Pan Arab Osteoporosis Society Guidelines for Osteoporosis Management. Mediterr J Rheumatol. 28(1):27–32. https://doi.org/10.31138/mjr.28.1.27CrossRefPubMedPubMedCentral

Al-Saleh Y, Al-Daghri NM, Sabico S, Alessa T, Al Emadi S, Alawadi F, Al Qasaabi S et al (2020) Diagnosis and management of osteoporosis in postmenopausal women in Gulf Cooperation Council (GCC) countries: consensus statement of the GCC countries’ osteoporosis societies under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Arch Osteoporos. 15(1):109. https://doi.org/10.1007/s11657-020-00778-5CrossRefPubMed

Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 4(6):368–81. https://doi.org/10.1007/BF01622200CrossRef

About IOF. https://www.osteoporosis.foundation/about-us#About-IOF

Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 7(4):390–406. https://doi.org/10.1007/BF01623782CrossRefPubMed

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285(6):785–95. https://doi.org/10.1001/jama.285.6.785CrossRef

10.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M et al (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 16(6):1016–9. https://doi.org/10.4158/ep.16.6.1016CrossRefPubMedPubMedCentral

11.

Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13(1):118. https://doi.org/10.1007/s11657-018-0510-0CrossRefPubMedPubMedCentral

12.

Saleh YAL, Sulimani RA, Alomary S, Alnajjar YI, Vandenput L, Liu E et al (2022) Incidence of hip fracture in Saudi Arabia and the development of a FRAX model. Arch Osteoporos 17(1):56. https://doi.org/10.1007/s11657-022-01085-xCrossRefPubMedPubMedCentral

13.

Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 16(1):609. https://doi.org/10.1186/s13018-021-02772-0CrossRefPubMedPubMedCentral

14.

Salari N, Darvishi N, Bartina Y, Larti M, Kiaei A, Hemmati M, Shohaimi S et al (2021) Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 16(1):669. https://doi.org/10.1186/s13018-021-02821-8CrossRefPubMedPubMedCentral

15.

GBD 2019 Fracture Collaborators (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev 2(9):e580–e592. https://doi.org/10.1016/S2666-7568(21)00172-0CrossRef

16.

Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, Lorentzon M et al (2020) Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 15(1):59. https://doi.org/10.1007/s11657-020-0706-yCrossRefPubMedPubMedCentral

17.

Aziziyeh R, Garcia Perlaza J, Saleem N, Sadat-Ali M, Elsalmawy A, McTavish RK, Duperrouzel C et al (2020) The burden of osteoporosis in Saudi Arabia: a scorecard and economic model. J Med Econ. 23(7):767–775. https://doi.org/10.1080/13696998.2020.1737536CrossRefPubMed

18.

MOH Publications. National Plan for Osteoporosis Prevention and Management in KSA.https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/Publications-2019-04-23-001.aspx

19.

Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST et al (2020) American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract 26(Suppl 1):1–46. https://doi.org/10.4158/GL-2020-0524SUPPLCrossRefPubMed

20.

Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104(3):235–238. https://doi.org/10.1007/s00223-018-00512-xCrossRefPubMedPubMedCentral

21.

Abdulla N, Alsaed OS, Lutf A, Alam F, Abdulmomen I, Al Emadi S, Harvey NC et al (2022) Epidemiology of hip fracture in Qatar and development of a country specific FRAX model. Arch Osteoporos. 17(1):49. https://doi.org/10.1007/s11657-022-01083-zCrossRefPubMedPubMedCentral

22.

Al-Daghri NM, Sabico S, Al-Saleh Y, Sulimani R, Aljohani NJ, Sheshah E, Alodhayani A et al (2021) The application of FRAX in Saudi Arabia. Arch Osteoporos. 16(1):166. https://doi.org/10.1007/s11657-021-01024-2CrossRefPubMed

23.

Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1–12. https://doi.org/10.1007/s00198-019-05176-3CrossRefPubMed

24.

Lorentzon M, Branco J, Brandi ML, Bruyère O, Chapurlat R, Cooper C, Cortet B et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 36(10):2811–2824. https://doi.org/10.1007/s12325-019-01063-9CrossRefPubMedPubMedCentral

25.

Al-Daghri NM, Hussain SD, Ansari MGA, Khattak MNK, Aljohani N, Al-Saleh Y, Al-Harbi MY et al (2021) Decreasing prevalence of vitamin D deficiency in the central region of Saudi Arabia (2008–2017). J Steroid Biochem Mol Biol 212:105920. https://doi.org/10.1016/j.jsbmb.2021.105920CrossRefPubMed

26.

Al-Daghri NM, Al-Saleh Y, Aljohani N, Sulimani R, Al-Othman AM, Alfawaz H, Fouda M et al (2017) Vitamin D status correction in Saudi Arabia: an experts’ consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Arch Osteoporos. 12(1):1. https://doi.org/10.1007/s11657-016-0295-yCrossRefPubMed

27.

Al Saleh Y, Beshyah SA, Hussein W, Almadani A, Hassoun A, Al Mamari A, Ba-Essa E et al (2020) Diagnosis and management of vitamin D deficiency in the Gulf Cooperative Council (GCC) countries: an expert consensus summary statement from the GCC vitamin D advisory board. Arch Osteoporos 15(1):35. https://doi.org/10.1007/s11657-020-0709-8CrossRefPubMed

28.

Rosenberg K (2022) Bisphosphonates likely beneficial for most older women with osteoporosis. Am J Nurs. 122(4):57. https://doi.org/10.1097/01.NAJ.0000827356.02005.29CrossRefPubMed

29.

Gao Y, Liu X, Gu Y, Song D, Ding M, Liao L, Wang J et al (2021) The effect of bisphosphonates on fracture healing time and changes in bone mass density: a meta-analysis. Front Endocrinol (Lausanne). 12:688269. https://doi.org/10.3389/fendo.2021.688269CrossRefPubMedPubMedCentral

30.

Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ et al (2018) Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. J Bone Miner Res. 33(5):783–794. https://doi.org/10.1002/jbmr.3384CrossRefPubMed

31.

Reginster J, Bianic F, Campbell R, Martin M, Williams SA, Fitzpatrick LA (2019) Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 30(7):1465–1473. https://doi.org/10.1007/s00198-019-04947-2CrossRefPubMedPubMedCentral

32.

Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N et al (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 17(1):58. https://doi.org/10.1007/s11657-022-01061-5CrossRefPubMedPubMedCentral

33.

Sun R, Chu Y, Gao Y, Cheng W, Gao S (2021) Efficacy and safety of endocrine therapy for breast-cancer prevention in high-risk premenopausal or postmenopausal women: a Bayesian network meta-analysis of nine randomized controlled trials. Menopause. 28(5):589–600. https://doi.org/10.1097/GME.0000000000001763CrossRefPubMed

34.

Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, Davis S (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone. 130:115081. https://doi.org/10.1016/j.bone.2019.115081CrossRefPubMed

35.

Kang F, Zou Q, Huang J (2022) The effects of raloxifene on endothelial function and inflammation in postmenopausal women: a meta-analysis of randomized controlled trials. Exp Gerontol. 159:111682. https://doi.org/10.1016/j.exger.2021.111682CrossRefPubMed

36.

Hanley DA, Adachi JD, Bell A, Brown V (2012) Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 66(12):1139–46. https://doi.org/10.1111/ijcp.12022CrossRefPubMed

37.

Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J, McDermott M et al (2020) A pooled analysis of fall incidence from placebo-controlled trials of denosumab. J Bone Miner Res. 35(6):1014–1021. https://doi.org/10.1002/jbmr.3972CrossRefPubMed

38.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 375(16):1532–1543. https://doi.org/10.1056/NEJMoa1607948CrossRefPubMed

39.

Curtis EM, Reginster JY, Al-Daghri N, Biver E, Brandi ML, Cavalier E, Hadji P et al (2022) Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 34(4):695–714. https://doi.org/10.1007/s40520-022-02100-4CrossRefPubMedPubMedCentral

40.

Singh S, Dutta S, Khasbage S, Kumar T, Sachin J, Sharma J, Varthya SB (2022) A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int. 33(1):1–12. https://doi.org/10.1007/s00198-021-06095-yCrossRefPubMed

41.

Li N, Hiligsmann M, Boonen A, van Oostwaard MM, de Bot RTAL, Wyers CE, Bours SPG et al (2021) The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. Osteoporos Int. 32(8):1517–1530. https://doi.org/10.1007/s00198-021-05911-9CrossRefPubMedPubMedCentral

42.

Al Saleh Y, El Seid ME, Ruhaiyem ME, Al Sayed F, Alkhairy A, Al Zaid S, Al Sayed O et al (2020) Characteristics and outcomes of osteoporotic hip fractures: treatment gaps in a tertiary care center in Riyadh. Saudi Arabia. Aging Clin Exp Res. 32(9):1689–1695. https://doi.org/10.1007/s40520-019-01377-2CrossRefPubMed

43.

Fouda M, Omair MA, Bin Nasser A, Dabbagh R, AlOmran N, AlWalan L, Aljabrain F et al (2020) Fragility hip fracture: incidence and care-gap at a tertiary hospital in Saudi Arabia. Int J Med Sci Curr Res 3(1):43–51

44.

Vandenput L, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. Osteoporos Int. 33(10):2103–2136. https://doi.org/10.1007/s00198-022-06435-6CrossRefPubMed

Title: Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society
Authors: Yousef Al-Saleh
Riad Sulimani
Shaun Sabico
Fahad M. Alshahrani
Mona A. Fouda
Mohammed Almohaya
Salwa B. Alaidarous
Hazem M. Alkhawashki
Mohammed Alshaker
Hanan Alrayes
Najla Saleh
Nasser M. Al-Daghri
Publication date: 01-12-2023
Publisher: Springer London
Keywords: Bisphosphonate
Osteoporosis
Osteoporosis
Denosumab
Denosumab
Published in: Archives of Osteoporosis / Issue 1/2023
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-023-01242-w

At a glance: The STEP trials

Springer Medicine

Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

An assessment of intervention thresholds for high fracture risk in Chile

Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials

Investigating the impact of a national educational program on patient adherence to osteoporosis medications

The aetiology of atypical bone health in individuals with Down syndrome

Current approaches to secondary prevention after hip fracture in England and Wales — an analysis of trends between 2016 and 2020 using the National Hip Fracture Database (NHFD)